Recently Listed Derma Firm Set for Phase III Acne Trial with NCE
This article was originally published in Scrip
Executive Summary
Cosmo Pharmaceuticals SpA spin-off Cassiopea SpA, the Swiss-listed, dermatology-focused company that raised CHF175.6m ($180m) in an initial public offering (IPO) in early July this year, is set to begin Phase III trials with its lead product candidate, a first-in-class acne treatment, in October. Some analysts have forecast $350m in peak US sales for Winlevi.
You may also be interested in...
Acne Pipeline Yields Three Disappointments, One Win So Far In 2017
The pipeline of acne therapeutics is packed with possibilities, but of four candidates to report data so far this year, only one was successful – Allergan's and Paratek's sarecycline, which may be a better antibiotic option, but doesn't give dermatologists a much-needed new mechanism of action.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.